Non-small-cell Lung Carcinoma
88
2
6
54
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
21 trials with published results (24%)
Research Maturity
54 completed trials (61% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.8%
13 terminated out of 88 trials
80.6%
-5.9% vs benchmark
19%
17 trials in Phase 3/4
39%
21 of 54 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 54 completed trials
Clinical Trials (88)
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer
Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease